5,570 Shares in West Pharmaceutical Services, Inc. $WST Purchased by Freestone Grove Partners LP

Freestone Grove Partners LP bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the 2nd quarter, Holdings Channel reports. The firm bought 5,570 shares of the medical instruments supplier’s stock, valued at approximately $2,000,000.

A number of other hedge funds also recently added to or reduced their stakes in WST. Wealth Alliance LLC lifted its position in shares of West Pharmaceutical Services by 3.8% during the 1st quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock valued at $237,000 after acquiring an additional 35 shares during the period. IFM Investors Pty Ltd grew its holdings in shares of West Pharmaceutical Services by 0.3% in the 1st quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock worth $3,452,000 after acquiring an additional 43 shares during the period. Compound Planning Inc. increased its stake in West Pharmaceutical Services by 3.6% in the 1st quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock valued at $307,000 after purchasing an additional 43 shares in the last quarter. Aptus Capital Advisors LLC increased its stake in West Pharmaceutical Services by 5.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after purchasing an additional 47 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its holdings in West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 50 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on WST. Morgan Stanley boosted their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Evercore reaffirmed an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and an average price target of $368.08.

West Pharmaceutical Services Stock Performance

West Pharmaceutical Services stock opened at $338.21 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The stock has a fifty day moving average of $350.55 and a two-hundred day moving average of $303.61. The company has a market capitalization of $23.80 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 2.42 and a beta of 1.15. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business’s revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.